Voices
Ilyas Sahin։ FDA Grants Accelerated Approval to Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
Ilyas Sahin/LinkedIn

Ilyas Sahin։ FDA Grants Accelerated Approval to Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer

Ilyas Sahin, Assistant Professor of Medicine at Harvard Medical School, shared on X:

“FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR).”

Read more: FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer.”

You can also read: FDA Grants Accelerated Approval: Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer

OncoDaily

cancer dMMR Dostarlimab FDA Ilyas Sahin microsatellite instability-high mismatch repair-deficient MSI-H OncoDaily Oncology rectal cancer